Goldline Pharmaceutical Limited
Bookbuilding IPO · BSE
- Price band
- ₹41 - ₹43
- Lot size
- 3,000 shares
- Issue amount
- ₹11.61 cr
- Total subscription
- 840.81×
- Opens
- 12 May 2026
- Closes
- 14 May 2026
- Allotment
- 15 May 2026
- Listing
- 19 May 2026
Offer at a glance
Issue overview
- Issue size
- 27,00,000 shares
- Face value
- ₹10 per share
- Minimum investment
- ₹1,23,000
- Fresh issue
- ₹11.61 cr
- Offer for sale
- ₹0 cr
- Registrar
- Bigshare Services Private Limited
- Listing exchange
- BSE
- Maximum investment
- ₹1,29,000
- Issue type
- Bookbuilding IPO
- Shares before issue
- 69,00,000
- Shares after issue
- 96,00,000
Lot sizes
| Category | Lots | Shares | Amount |
|---|---|---|---|
| RETAIL | 2 | 6,000 | ₹2,58,000 |
| sHNI | 3 | 9,000 | ₹3,87,000 |
| bHNI | 8 | 24,000 | ₹10,32,000 |
Share reservation
Subscription & GMP
Subscription by category
Reported 14 May 2026
GMP history
Day-wise demand
Application-wise demand
| Category | Reserved applications | Applied applications |
|---|---|---|
| QIB | 0 | 85 |
| NIB | 0 | 33,760 |
| RETAIL | 150 | 1,32,173 |
| EMPLOYEES | 0 | 0 |
| HNIs(10L +) | 29 | 20,429 |
| HNIs (2-10L) | 14 | 13,331 |
| Shareholder | 0 | 0 |
Subscription demand
Amounts in ₹ crore. HNI subcategories are included in the NII total.
| Category | Offered | Demand |
|---|---|---|
| QIBs | 2.32 | 418.46 |
| FIIs | 0 | 109.38 |
| Others | 0 | 309.05 |
| RETAIL | 3.87 | 3,410.06 |
| HNIs 2+ | 0.56 | 556.67 |
| HNIs 10+ | 1.12 | 2,231.16 |
Financial performance
Company financials
In Crores · Reported periods may include interim results.
Key performance indicators
| Metric | Dec-25 | Mar-25 | Mar-24 |
|---|---|---|---|
| EPS | 3.22 | 4.1 | 3.01 |
| ROE | 21.02 | 35.83 | 31.31 |
| ROCE | 0 | 0 | 0 |
| RONW | 0 | 0 | 0 |
| PRE IPO(PE) | 0 | 10.47 | 0 |
| POST IPO(PE) | 14.56 | 0 | 0 |
Values and labels as reported in the issue data.
Peer comparison
| Company | P/E(X) | CMP* (₹) | Face value (₹) | NAV/Share (₹) | RONW(%) | EPS (Basic) (₹) |
|---|---|---|---|---|---|---|
| Goldline Pharmaceutical Limited | 10.47 | 0 | 10 | 12.38 | 27.37 | 4.1 |
| Mono Pharmacare Limited | 7.57 | 0 | 10 | 17.66 | 9.9 | 1.75 |
| Chandra Bhagat Pharma Limited | 28.94 | 0 | 10 | 39.72 | 2.86 | 1.14 |
Company information
Company profile
Goldline Pharmaceuticals markets pharmaceutical products under the “Goldline” brand, offering a wide range of medicines across five divisions—Goldline Pharma, Goldline Cardinal, Goldline Aayushman, Goldline InLife, and Goldline Wellness. These products cater to various medical specialties including physicians, cardiologists, pediatricians, orthopedics, neurologists, critical care experts, and cancer supportive care. Instead of manufacturing medicines directly, the company works with third-party manufacturers who produce products based on its research and specifications while ensuring quality and regulatory compliance. Goldline sells its products through a network of distributors, retailers, and wholesalers, and also supports hospitals and healthcare providers with procurement and supply services. The company currently partners with 15 manufacturers and 7 distributors, with operations spread across states like Maharashtra, Madhya Pradesh, Odisha, Jharkhand, Tamil Nadu, Rajasthan, and Bihar.
Strengths
- Asset-Light & Scalable Business Model: Outsourced manufacturing approach reduces capital requirements and supports expansion.
- Diversified Pharmaceutical Portfolio: Wide range of products across multiple therapeutic segments reduces dependency on one category.
- Strong Distribution & Supplier Network: Established relationships with manufacturers and distributors ensure smooth operations.
Risk factors
- Dependence on Third-Party Manufacturers: Reliance on external manufacturers may impact quality control and supply continuity.
- Regulatory Compliance Risks: Pharmaceutical industry is highly regulated and subject to strict approvals and standards.
- Limited Geographic Presence: Operations concentrated in selected Indian states may restrict nationwide growth.
Promoters
Amol Laxmikant Mujumdar
Swapan Premprakash Khandelwal
Registrar & documents
Lead manager
Cumulative Capital Private Limited
Registrar & contacts
Bigshare Services Private Limited
[email protected]Official registrar portal ↗Check allotment status on registrar →Registered office
103, F-1, Leela Apartment, Shilpa HSG Society, Near Saptagiri Nagar, Shanidham, Narendra Nagar, Nagpur, Maharashtra, 440015
+91 712 2786666
[email protected]Company website ↗Frequently Asked Questions
What is Goldline Pharmaceutical IPO GMP today?
As of today, Goldline Pharmaceutical IPO Grey Market Premium (GMP) is reported at +₹12 per share. Based on the upper price band of ₹43, the estimated listing price is ₹55 (+27.9% expected listing gain). Please note that GMP is an unofficial market estimate for sentiment tracking and does not guarantee the actual listing price.
What is the lot size and minimum investment for Goldline Pharmaceutical IPO?
The minimum bid lot size for Goldline Pharmaceutical IPO is 3,000 shares. At the cut-off price of ₹43 per share, retail investors need a minimum application amount of ₹1,29,000 per lot. Retail applicants can apply for a maximum of 1 lots (up to ₹2,00,000).
When will Goldline Pharmaceutical IPO allotment status be announced?
The allotment status for Goldline Pharmaceutical IPO is scheduled to be finalized on 15 May 2026. If you applied for the IPO, you can verify whether shares have been allocated to your Demat account through Bigshare Services Private Limited's official portal or via BSE/NSE allotment portals.
How can I check Goldline Pharmaceutical IPO allotment status online by PAN?
To check Goldline Pharmaceutical IPO allotment status: 1) Visit the registrar portal (Bigshare Services Private Limited) or the BSE IPO allotment page. 2) Select 'Goldline Pharmaceutical Limited' from the company dropdown. 3) Choose 'PAN' as your identification mode and enter your 10-digit Permanent Account Number. 4) Click 'Search' to view your allotted share quantity and application status.
Explore More IPO Analysis & Live Tools
Compare the price band and required investment with company financials and official offer documents. Grey market premium (GMP) figures are indicative market estimates collected from primary market brokers and do not establish the official listing price.